Drugs / SJP-0132
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Japan (PMDA) | — | dry eye syndrome | 2025-01-17 | “本日、日本において「ドライアイ」の適応で製造販売承認申請を行いましたことをお知ら” mochida.co.jp ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04139122 | Oct 2019 → Mar 2020 | dry eye syndrome | Senju Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06717152 | Dec 2024 → Jul 2025 | dry eye syndrome | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | Mochida Pharmaceutical Company, Ltd. | Regulatory Obtained manufacturing and marketing approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient mochida.co.jp ↗
has obtained manufacturing and marketing approval in Japan as of December 22, 2025. |
| 2025-12-22 | Mochida Pharmaceutical Company, Ltd. | Regulatory 世界初、TRPV1拮抗作用を持つドライアイ治療薬「アバレプト懸濁性点眼液0.3%」国内承認取得のお知らせ mochida.co.jp ↗ |
| 2025-01-17 | Mochida Pharmaceutical Company, Ltd. | Regulatory ドライアイ治療薬「SJP-0132点眼液」に関する製造販売承認申請のお知らせ mochida.co.jp ↗ |
| 2024-07-16 | Mochida Pharmaceutical Company, Ltd. | Results ドライアイ治療薬「SJP-0132点眼液」に関する国内第III相臨床試験終了のお知らせ mochida.co.jp ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | Mochida Pharmaceutical Company, Ltd. | Obtained manufacturing and marketing approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient mochida.co.jp ↗ |
| 2025-12-22 | Mochida Pharmaceutical Company, Ltd. | 世界初、TRPV1拮抗作用を持つドライアイ治療薬「アバレプト懸濁性点眼液0.3%」国内承認取得のお知らせ mochida.co.jp ↗ |
| 2025-01-17 | Mochida Pharmaceutical Company, Ltd. | ドライアイ治療薬「SJP-0132点眼液」に関する製造販売承認申請のお知らせ mochida.co.jp ↗ |
| 2024-07-16 | Senju Pharmaceutical Co., Ltd. | ドライアイ治療薬「SJP-0132 点眼液」に関する国内第Ⅲ相臨床試験終了のお知らせ senju.co.jp ↗ |
| 2024-07-16 | Mochida Pharmaceutical Company, Ltd. | ドライアイ治療薬「SJP-0132点眼液」に関する国内第III相臨床試験終了のお知らせ mochida.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SJP-0132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04139122 ↗ |
| Route | Topical | “SJP-0132 is administered as an eye drop” NCT04139122 ↗ |